key: cord-1001262-52821twe authors: Theoharides, Theoharis C.; Antonopoulou, Smaragdi; Demopoulos, Constantinos A. title: CoVid-19, Microthromboses and Platelet Activating Factor (PAF) date: 2020-08-17 journal: Clin Ther DOI: 10.1016/j.clinthera.2020.08.006 sha: 24fa1ad8de2d6090a155e6aa0b31e83e36df9907 doc_id: 1001262 cord_uid: 52821twe Abstract Recent papers report elevated markers of coagulation, endothelial injury and microthromboses in lungs from deceased CoVid-19 patients. Platelets are critical in the formation of thrombi and their most potent trigger is platelet activating factor (PAF), the structure of which was elucidated by Demopoulos and colleagues, who also described its semisynthetic preparation. in 1979. PAF is produced by cells involved in host defense and its biological actions bear similarities with CoVid-19 disease manifestations, including pulmonary microthromboses and inflammation, possibly via activation of mast cells. The histamine-1 receptor antagonist rupatadine was developed to have anti-PAF activity and also inhibits activation of human mast cells in response to PAF. Rupatadine could be repurposed for CoVid-19 prophylaxis. Ackermann and colleagues recently reported the presence of severe endothelial injury, and widespread pulmonary microthromboses accompanied with increased angiogenesis in lungs from deceased CoVid-19 patients. 1 These results support other recent publications from different centers showing the presence of elevated coagulation markers [2] [3] [4] and microthromboses in the lung and other organs of CoVid-19 patients. [5] [6] [7] [8] Most recently, platelet activation and aggregation has been reported in severe CoVid-19 patients, [9] [10] but the triggers of these processes were not discussed. The most potent trigger of platelet aggregation is platelet activating factor (PAF), first discovered by Benvesiste in 1971. 11 Demopoulos et al. elucidated its structure as a glyceryl-ether lipid (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and also described its semisynthetic preparation. in 1979. 12 PAF is produced by cells involved in host defense and its biological actions bear similarities with CoVid-19 disease manifestations. 13 It was recently reported that platelets, via release of PAF, trigger perivascular mast cell activation, leading to inflammation. 14 Moreover, mast cell degranulation associated with insterstitial edema and immunothrombosis was just reported in alveolar septa of deceased patients with Mast cells are a rich source of PAF and are plentiful in the lungs, 16 where they may contribute to CoVid-19. 17 We had reported that levels of PAF were increased in allergic rhinitis 18 and chronic urticaria, 19 both of which involve activation of mast cells. Moreover, PAF appears to play a central role in inflammation. 20, 21 In this context, it is important to note that innate immunity to CoVid-19 appears to involve activated T-cells and specific antibodies, 22,23 lung pathology seen in severe acute respiratory syndrome (SARS) associated with CoVid-19 is due to release of a "storm" of pro-J o u r n a l P r e -p r o o f inflammatory cytokines. 24, 25 Mast cells are one of the richest sources of such cytokines, especially IL-6, 26,27 which has been implicated in CoVid-19. 28 Since mast cells are involved in lung diseases, it makes sense that such patients would be even more susceptible to pulmonary complications of Given the above findings, it would make sense to try to inhibit the action of PAF (Fig. 1) . A number of PAF inhibitors have been synthesized, but are not available for clinical use [30] [31] [32] except for the histamine-1 receptor antagonist rupatadine, which was developed to also specifically exhibit anti-PAF activity. 33 We reported that rupatadine also inhibits activation of human mast cells in response to PAF (Fig. 1) . 34 Rupatadine could, therefore, be repurposed for at least CoVid-19 prophylaxis. Interestingly, certain natural flavonoids also have anti-PAF activity, 35, 36 in addition to their having anti-inflammatory actions and ability to block Conora virus binding to target cells. 17 All authors contributed equally for this manuscript. J o u r n a l P r e -p r o o f Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19 The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19 The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications Novels insights on the pulmonary vascular consequences of COVID-19 Autopsy in suspected COVID-19 cases Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19) Platelet activation and plateletmonocyte aggregates formation trigger tissue factor expression in severe COVID-19 patients Leukocyte-dependent histamine release from rabbit platelets : The role of IgE basophils and a platelet-activating factor Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators) Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives Platelets trigger perivascular mast cell degranulation to cause inflammatory responses and tissue injury Mast cell degranulation in alveolar septa and SARS-COV-2: A pathogenic pathway linking insterstitial edema to immunothrombosis Mast Cells, Mastocytosis, and Related Disorders COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin PAF of biological fluids in disease: Blood levels in allergic rhinitis Increased platelet activating factor levels in chronic spontaneous urticaria predicts refractoriness to antihistamine treatment: an observational study The role of platelet-activating factor in inflammation PAF, a potent lipid mediator Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19 Clinical and immunological features of severe and moderate coronavirus disease 2019 The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): antiinflammatory strategies Mast cells and inflammation Mast cells as sources of cytokines, chemokines, and growth factors Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 Association Between Clinical Manifestations and Prognosis in Patients with COVID-19 Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I) A review on platelet activating factor inhibitors: Could a new class of potent metal-based anti-inflammatory drugs induce anticancer properties? The Potential Role of Dietary Platelet-Activating Factor Inhibitors in Cancer Prevention and Treatment A new selective histamine H1 receptor and platelet activation factor (PAF) antagonist Rupatadine inhibits inflammatory mediator release from human laboratory of allergic diseases 2 cultured mast cells stimulated by platelet-activating factor Inhibition of lysoPAF acetyltransferase activity by flavonoids Modulation by flavonoids of PAF and related phospholipids in endothelial cells during oxidative stress